CORRECTED-Spero Therapeutics Q4 revenue nearly triples, swings to profit

Reuters03-27 04:22
CORRECTED-Spero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 revenue nearly triples, swings to profit

Corrects Q4 EPS to $0.53 from $0.56 in Key Details table

Overview

  • US biopharma firm's Q4 revenue nearly tripled yr/yr, driven by higher collaboration revenue

  • Q4 net income swung to profit from loss a year earlier

  • Company expects cash reserves to fund operations into 2028

Outlook

  • Spero estimates cash and equivalents will fund operations into 2028

  • Company continues to explore opportunities to expand its clinical-stage portfolio

Result Drivers

  • COLLABORATION REVENUE - Co said Q4 revenue increase was mainly due to higher collaboration revenue from GSK and Pfizer agreements

  • MILESTONE PAYMENT - Co received $25 mln milestone payment from GSK in Q1 2026 triggered by tebipenem HBr NDA resubmission

  • LOWER R&D COSTS - Research and development expenses fell due to decreased clinical trial activity related to the PIVOT-PO trial

Company press release: ID:nGNX41Q7PX

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

$0.53

Q4 Net Income

$31.52 mln

Q4 Income From Operation

$31.41 mln

Q4 Operating Expenses

$9.89 mln

Analyst Coverage

  • The one available analyst rating on the shares is "hold"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Spero Therapeutics Inc is $4.00, about 66% above its March 25 closing price of $2.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment